Topiramate 200 to 400 mg vs placebo: Withdrawals due to adverse events
Topiramate 200 to 400 mg probably leads to higher adverse event withdrawals compared with placebo (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Topiramate 200 to 400 mg vs placebo Adverse event withdrawals · neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy) Topiramate 200 to 400 mg probably leads to higher adverse event withdrawals compared with placebo (moderate certainty). Topiramate for neuropathic pain and fibromyalgia in adults (2013) · Cochrane Headline outcomes only | RR 3.4 [4.3, 7.1] | 1038 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Topiramate for neuropathic pain and fibromyalgia in adults 2013 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.